Skip to main content
Erschienen in: Pediatric Nephrology 10/2003

01.10.2003 | Original Article

Leptin, soluble leptin receptor, and transforming growth factor-β1 levels in minimal change nephrotic syndrome

verfasst von: Necla Buyan, Ozan Özkaya, Aysun Bideci, Oğuz Söylemezoğlu, Peyami Cinaz, Sevim Gönen, Süleyman Kalman, Sevcan Bakkaloğlu, Enver Hasanoğlu

Erschienen in: Pediatric Nephrology | Ausgabe 10/2003

Einloggen, um Zugang zu erhalten

Abstract

Leptin may contribute to renal pathology in some situations by stimulating transforming growth factor-β1 (TGF-β1) synthesis. The soluble leptin receptor (sOb-R) is a transport protein contributing to binding and activation of circulating leptin. We investigated the interaction between serum and urinary leptin, TGF-β1, and serum sOb-R levels in 38 patients with minimal change nephrotic syndrome (MCNS) aged between 6 and 12 years and 10 age- and sex-matched healthy controls (group III). Patients were divided into two groups: group I, proteinuria exceeding >40 mg/m2 per hour and group II, patients in remission. Serum leptin levels in group I were significantly lower than those in group II and group III (P=0.011, P=0.007, respectively). There was a negative correlation between serum leptin levels and proteinuria (r=–0.52, P=0.02) as well as between serum leptin and sOb-R levels (r=–0.82, P=0.000) in group I. Urine leptin and sOb-R levels in group I were significantly higher than in group II (P=0.0021, P=0.001, respectively) and group III (P=0.07, P=0.009, respectively). Serum TGF-β1 levels in healthy controls (406±424 pg/ml) were significantly lower than those in groups I and II (P=0.004, P=0.000, respectively). However, no significant correlation was found between the serum TGF-β1 and leptin levels in MCNS patients. In conclusion, low serum leptin, high serum TGF-β1 and sOb-R levels, and elevated urine leptin concentrations were observed at the onset of MCNS. Since long-term proteinuria and leptinuria might be associated with the progression of renal damage, future in vivo and in vitro studies are needed to explain the interaction between these parameters in different types of nephrotic syndrome.
Literatur
1.
Zurück zum Zitat Stenvinkel P, Lönnqvist F, Schalling M (1999) Molecular studies of leptin: implications for renal disease. Nephrol Dial Transplant 14:1103–1112CrossRefPubMed Stenvinkel P, Lönnqvist F, Schalling M (1999) Molecular studies of leptin: implications for renal disease. Nephrol Dial Transplant 14:1103–1112CrossRefPubMed
2.
3.
Zurück zum Zitat Lahlou N, Issad T, Lebouc Y, Carel JC, Camoin L, Roger M, Girard J (2000) Soluble leptin receptor in serum of subjects with complete resistance to leptin: relation to fat mass. Diabetes.49:1347–1352 Lahlou N, Issad T, Lebouc Y, Carel JC, Camoin L, Roger M, Girard J (2000) Soluble leptin receptor in serum of subjects with complete resistance to leptin: relation to fat mass. Diabetes.49:1347–1352
4.
Zurück zum Zitat Lahlou N, Clement K, Carel JC, Vaisse C, Lotton C, Le Bihan Y, Bosdevant A, Lebouc Y, Fraguel P, Roger M, Guy-Grand B (2002) Mutations in the human leptin and leptin receptor genes as models of serum leptin receptor regulation. Diabetes 51:2105–2112PubMed Lahlou N, Clement K, Carel JC, Vaisse C, Lotton C, Le Bihan Y, Bosdevant A, Lebouc Y, Fraguel P, Roger M, Guy-Grand B (2002) Mutations in the human leptin and leptin receptor genes as models of serum leptin receptor regulation. Diabetes 51:2105–2112PubMed
5.
Zurück zum Zitat Wolf G, Hamann A, Han DC, Helmchen U, Thaiss F, Ziyadeh FN, Stahl RAK (1999) Leptin stimulates proliferation and TGFβ expression in renal glomerular endothelial cells: potential role in glomerulosclerosis. Kidney Int 56:860–872CrossRefPubMed Wolf G, Hamann A, Han DC, Helmchen U, Thaiss F, Ziyadeh FN, Stahl RAK (1999) Leptin stimulates proliferation and TGFβ expression in renal glomerular endothelial cells: potential role in glomerulosclerosis. Kidney Int 56:860–872CrossRefPubMed
6.
Zurück zum Zitat Ballerman B (1999) A role for leptin in glomerulosclerosis? Kidney Int 56:1154–1155 Ballerman B (1999) A role for leptin in glomerulosclerosis? Kidney Int 56:1154–1155
7.
Zurück zum Zitat International Study of Kidney Disease in Children (1978) The nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at the time of diagnosis. Kidney Int 13:159–165PubMed International Study of Kidney Disease in Children (1978) The nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at the time of diagnosis. Kidney Int 13:159–165PubMed
8.
Zurück zum Zitat Liu C, Liu X, Barry G, Ling N, Maki RA, Souza EBD (1997) Expression and characterization of a putative high affinity human soluble leptin receptor. Endocrinology 138:3548–3554PubMed Liu C, Liu X, Barry G, Ling N, Maki RA, Souza EBD (1997) Expression and characterization of a putative high affinity human soluble leptin receptor. Endocrinology 138:3548–3554PubMed
9.
Zurück zum Zitat Schroth M, Gröschl M, Dörr HG, Blum WF, Rascher W, Dötsch J (2001) Renal loss of leptin in patients with nephrotic syndrome. Eur J Endocrinol 145:463–468PubMed Schroth M, Gröschl M, Dörr HG, Blum WF, Rascher W, Dötsch J (2001) Renal loss of leptin in patients with nephrotic syndrome. Eur J Endocrinol 145:463–468PubMed
10.
Zurück zum Zitat Özata M, Oktenli Ç, Özgürtaş T, Bulucu F, Çağlar K, Bingöş, Vural A, Özdemir I Çağlayan (2002) Increased fasting plasma acylation-stimulating protein concentrations in nephrotic syndrome. J Clin Endocrinol Metab 87:853–859 Özata M, Oktenli Ç, Özgürtaş T, Bulucu F, Çağlar K, Bingöş, Vural A, Özdemir I Çağlayan (2002) Increased fasting plasma acylation-stimulating protein concentrations in nephrotic syndrome. J Clin Endocrinol Metab 87:853–859
11.
Zurück zum Zitat Tan JT, Patel BK, Kaplan LM, Koenig JL, Hooi SC (1998) Regulation of leptin expression and secretion by corticosteroids and insulin. Implications for body weight. Endocrine 8:85–92PubMed Tan JT, Patel BK, Kaplan LM, Koenig JL, Hooi SC (1998) Regulation of leptin expression and secretion by corticosteroids and insulin. Implications for body weight. Endocrine 8:85–92PubMed
12.
Zurück zum Zitat Lewandowski K, Randeva HS, O'Callaghan CJ, Horn R, Medley GF, Hillhouse EW, Brabant G, O'Hare P (2001) Effects of insulin and glucocorticoids on the leptin system are mediated through free leptin. Clin Endocrinol (Oxf) 54:533–539 Lewandowski K, Randeva HS, O'Callaghan CJ, Horn R, Medley GF, Hillhouse EW, Brabant G, O'Hare P (2001) Effects of insulin and glucocorticoids on the leptin system are mediated through free leptin. Clin Endocrinol (Oxf) 54:533–539
13.
Zurück zum Zitat Taylor GM, Neuhaus TJ, Shah V, Dillon S, Barrat TM (1997) Charge and size selectivity of proteinuria in children with idiopathic nephrotic syndrome. Pediatr Nephrol 11:404–410CrossRefPubMed Taylor GM, Neuhaus TJ, Shah V, Dillon S, Barrat TM (1997) Charge and size selectivity of proteinuria in children with idiopathic nephrotic syndrome. Pediatr Nephrol 11:404–410CrossRefPubMed
14.
Zurück zum Zitat Tryggvason K, Wartiovaara J (2001) Molecular basis of glomerular permselectivity. Curr Opin Nephrol Hypertens 10:543–549CrossRefPubMed Tryggvason K, Wartiovaara J (2001) Molecular basis of glomerular permselectivity. Curr Opin Nephrol Hypertens 10:543–549CrossRefPubMed
15.
Zurück zum Zitat Lammert A, Kiess W, Bottner A, Glasow A, Kratzsch J (2001) Soluble leptin receptor represents the main leptin binding activity in human blood. Biochem Biophys Res Commun 18:982–988CrossRef Lammert A, Kiess W, Bottner A, Glasow A, Kratzsch J (2001) Soluble leptin receptor represents the main leptin binding activity in human blood. Biochem Biophys Res Commun 18:982–988CrossRef
16.
Zurück zum Zitat Monteleone P, Fabrazzo M, Tortorella A, Fuschino A, Maj M (2002) Opposite modifications in circulating leptin and soluble leptin receptor across the eating disorder spectrum. Mol Psychiatry 7:17CrossRefPubMed Monteleone P, Fabrazzo M, Tortorella A, Fuschino A, Maj M (2002) Opposite modifications in circulating leptin and soluble leptin receptor across the eating disorder spectrum. Mol Psychiatry 7:17CrossRefPubMed
17.
Zurück zum Zitat Stejskal D, Bartek J, Ruzicka V, Stejskal P, Jedelsky L, Oral I, Horalik D, Zurek M (1999) Determination of leptin receptor in the serum and relations to laboratory and anthropological parameters in patients with atherosclerotic complications. Acta Univ Palacki Olomuc Fac Med 142:89–92PubMed Stejskal D, Bartek J, Ruzicka V, Stejskal P, Jedelsky L, Oral I, Horalik D, Zurek M (1999) Determination of leptin receptor in the serum and relations to laboratory and anthropological parameters in patients with atherosclerotic complications. Acta Univ Palacki Olomuc Fac Med 142:89–92PubMed
18.
Zurück zum Zitat Chan JL, Bluher S, Yiannakouris N, Suchard MA, Kratzsch J, Mantzoros CS (2002) Regulation of circulating soluble leptin receptor levels by gender, adiposity, sex steroids, and leptin: observational and interventional studies in humans. Diabetes 51:2105–2112PubMed Chan JL, Bluher S, Yiannakouris N, Suchard MA, Kratzsch J, Mantzoros CS (2002) Regulation of circulating soluble leptin receptor levels by gender, adiposity, sex steroids, and leptin: observational and interventional studies in humans. Diabetes 51:2105–2112PubMed
Metadaten
Titel
Leptin, soluble leptin receptor, and transforming growth factor-β1 levels in minimal change nephrotic syndrome
verfasst von
Necla Buyan
Ozan Özkaya
Aysun Bideci
Oğuz Söylemezoğlu
Peyami Cinaz
Sevim Gönen
Süleyman Kalman
Sevcan Bakkaloğlu
Enver Hasanoğlu
Publikationsdatum
01.10.2003
Verlag
Springer-Verlag
Erschienen in
Pediatric Nephrology / Ausgabe 10/2003
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-003-1221-2

Weitere Artikel der Ausgabe 10/2003

Pediatric Nephrology 10/2003 Zur Ausgabe

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.